Opendata, web and dolomites


Demonstration of a synthetic biology-driven biomanufacturing platform for adaptable cost-effective production of high-value low volume biologics opportunities.

Total Cost €


EC-Contrib. €






Project "SYNBIOMAN" data sheet

The following table provides information about the project.


Organization address
city: ROSLIN
postcode: EH25 9PP

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.4. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology)
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-08-01   to  2016-12-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INGENZA LIMITED UK (ROSLIN) coordinator 50˙000.00


 Project objective

Ingenza will address an unmet industry need at the European level for an enabling biologics manufacturing and refinement platform targeting difficult-to-express protein structures and/or hard-to-handle potent products that requires novel, efficient, low volume manufacturing. This is a niche high-value market but the customisation and flexibility needed to address such complexity means the market is not of interest to larger established Contract Development Manufacturing Organisations. Ingenza will deliver and demonstrate a novel synthetic biology (SynBio) driven manufacturing platform that is EMA and FDA certified for GMP production of investigational and commercial biologics. This includes transitioning SynBio tools developed for industrial biotechnology towards addressing opportunities in the growing biopharmaceutical sector (CAGR 9.5%); delivering innovative biomanufacturing capabilities beyond the current state-of-the-art. To achieve this goal Ingenza will deploy its inABLE® suite of proprietary SynBio tools including those for high throughput gene cloning, efficient strain screening/construction and effective bioprocess development - all integrated with state of the art single use biofermentors and downstream process technologies. Ingenza’s biomanufacturing process is at TRL 6 moving towards TRL 9. The project is supported by five novel biologics developers in the EU and US, one of which will provide the case study at Phase 2 using an microbial cell factory.

The Phase 1 project aims to (i) define the activities required to achieve Good Manufacturing Practice compliance for a first highly potent target biologic, (ii) demonstrate scale up, (iii) test the market to ensure a robust business model and (iv) confirm freedom to operate. Ingenza expect to reach the market in 2019 initially creating 10 high value biomanufacturing jobs. Predicted revenues should achieve an ROI of 1:9 after 6 years and 27new jobs.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SYNBIOMAN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SYNBIOMAN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.4.;H2020-EU.2.3.1.)

FlexiBiome (2018)

Next Generation Microbiome Platform

Read More  

SEQURE (2018)

Targeted complete next-generation sequencing for companion diagnostics and personalized treatment of cancer

Read More  

sFilm-FS (2018)

Fibrin sealant for anastomotic leaks and haemostasis

Read More